about
Beta cell antigens in type 1 diabetes: triggers in pathogenesis and therapeutic targetsSecondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition.Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominanceIRAP identifies an endosomal compartment required for MHC class I cross-presentationA neural network model approach to the study of human TAP transporterCalreticulin exposure dictates the immunogenicity of cancer cell deathER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cellsDistinct molecular mechanisms leading to deficient expression of ER-resident aminopeptidases in melanoma.CTL escape mediated by proteasomal destruction of an HIV-1 cryptic epitopeIdentifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors.Substrate selection by transporters associated with antigen processing occurs during peptide binding to TAP.Immunization of HLA class I transgenic mice identifies autoantigenic epitopes eliciting dominant responses in type 1 diabetes patients.A detailed analysis of the murine TAP transporter substrate specificityCompartmentalized MHC class I antigen processing enhances immunosurveillance by circumventing the law of mass action.Lysyl tRNA synthetase is required for the translocation of calreticulin to the cell surface in immunogenic death.Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure.Study of antigen-processing steps reveals preferences explaining differential biological outcomes of two HLA-A2-restricted immunodominant epitopes from human immunodeficiency virus type 1.Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone.Beyond the proteasome: trimming, degradation and generation of MHC class I ligands by auxiliary proteases.No major role for insulin-degrading enzyme in antigen presentation by MHC molecules.Differential proteasomal processing of hydrophobic and hydrophilic protein regions: contribution to cytotoxic T lymphocyte epitope clustering in HIV-1-Nef.A proteasome-dependent, TAP-independent pathway for cross-presentation of phagocytosed antigen.Pancreatic β-Cells Limit Autoimmune Diabetes via an Immunoregulatory Antimicrobial Peptide Expressed under the Influence of the Gut Microbiota.Characteristics of peptide and major histocompatibility complex class I/beta 2-microglobulin binding to the transporters associated with antigen processing (TAP1 and TAP2)ZnT8 is a major CD8+ T cell-recognized autoantigen in pediatric type 1 diabetes.Catalytic site inhibition of insulin-degrading enzyme by a small molecule induces glucose intolerance in miceComplexity, contradictions, and conundrums: studying post-proteasomal proteolysis in HLA class I antigen presentation.Cytotoxic T cells specific for glutamic acid decarboxylase in autoimmune diabetesActivation of cellular death programs associated with immunosenescence-like phenotype in TPPII knockout miceUnexpected lack of specificity of a rabbit polyclonal TAP-L (ABCB9) antibody.Ecto-calreticulin in immunogenic chemotherapy.Screening Identifies Thimerosal as a Selective Inhibitor of Endoplasmic Reticulum Aminopeptidase 1.Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death.T cells in the pathogenesis of type 1 diabetes.ERAP1-ERAP2 dimers trim MHC I-bound precursor peptides; implications for understanding peptide editing.HIV-1 adaptation to antigen processing results in population-level immune evasion and affects subtype diversification.Providing ligands for MHC class I molecules.Post-proteasomal and proteasome-independent generation of MHC class I ligands.Running the gauntlet: from peptide generation to antigen presentation by MHC class I.Insulin-regulated aminopeptidase and its compartment in dendritic cells.
P50
Q26751244-7C2EBE81-AF56-4A4B-80A6-8ACAE47744E9Q27653882-AD7BF67A-F251-417E-A568-844D6DE10F49Q27655357-661A8F13-A3DB-4F77-BCAA-5AB7E3DCF81BQ28114994-43685585-FA54-4787-94BE-4EE08BD870B0Q28208577-566B4743-BE74-4683-862E-75F3A801D216Q28280438-6C61BB7A-E445-4114-B1B3-EDBD9E83985DQ28506676-0F2E3209-BC3E-47AE-AD8C-4ED4C7B5678EQ30318705-6EFA9F7A-D472-4023-9826-57A5B21AF52FQ31010282-A13A3745-EF3F-473B-8DEC-E5122BB62CE8Q31151998-8914C539-CC16-49C6-8CF4-AB44408B6EC4Q31984305-6763F8B0-0854-468B-B9B3-908747F99CD6Q33285140-A9C40CA3-4B8C-4FA6-83B7-E5D4AACB093BQ33342843-269191B5-2068-448E-A91F-AA70B0256B68Q33859470-971255B7-A98E-4B52-B5A7-4402E2BDE00CQ34130711-80340404-9F0B-408C-B8F7-BACE83945D76Q34335039-9F1178D4-8B77-4558-A9EF-3979132F0056Q34348731-7082DF06-19DB-4A43-A730-1BBC8A4AFC3BQ34612686-9CC42CE1-D3A5-4F97-A7CF-831B1D010191Q34801827-F9A74329-D124-4ABC-80EE-0299FF780031Q35091713-D31898E0-CA2D-4005-A344-2160E5FD398EQ35146742-CBAA2B7D-483B-4840-A841-00916C805A66Q35632808-9D0D7A7B-9016-4FD1-A3BF-DDC363D9A10EQ35740373-58A69C4F-DD97-4C94-91A3-32F51E2AD240Q35999694-93C0F935-D301-4FB1-9A29-6C55D0CA779DQ36047531-C851B920-0464-432F-86C7-9E2915BAC953Q36087916-3FBDA352-0B64-4F3F-96AA-EA4D087FD2DBQ36266433-241D5787-F380-403C-96EA-A3EF5E067B89Q36364761-C1855240-DCCF-4137-8C7B-59D1511A14D0Q36516221-6B829799-FB79-4B25-A280-303BFB0BF2CDQ36971359-E94361F4-010F-4E11-8416-1A886E1FB596Q36990570-A114479B-F686-4D8E-8E80-A43089271C77Q37101562-BFCB9324-26DE-4E36-98F5-7D85DB1652B8Q37133168-49185850-A376-4FD5-B871-81E73006E736Q37150506-02CA60A7-CBDD-404E-8A17-CAEA8BDF16F2Q37168911-F403677E-AC8A-42E8-9F5A-0FEB642FB45BQ37734787-633F3D88-82A2-4299-A897-2903ADAD0072Q37848711-E9ADF345-91EA-4324-8851-88C1B7B6E994Q37851391-A3E8DFC7-D1D8-4CE7-8368-D153283F7765Q37898727-F3B060C2-241E-4A9F-81D0-B09A332EDD85Q38057518-52E6DDE9-1346-4E78-BA7D-EBD0AA9A3DEF
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Peter M van Endert
@ast
Peter M van Endert
@en
Peter M van Endert
@es
Peter M van Endert
@nl
Peter M van Endert
@sl
type
label
Peter M van Endert
@ast
Peter M van Endert
@en
Peter M van Endert
@es
Peter M van Endert
@nl
Peter M van Endert
@sl
prefLabel
Peter M van Endert
@ast
Peter M van Endert
@en
Peter M van Endert
@es
Peter M van Endert
@nl
Peter M van Endert
@sl
P106
P1153
7006512894
P21
P31
P496
0000-0003-3782-0750